Vertex Pharmaceuticals Incorporated VRTX
Set alert
564.48 USD +5.60 +1.00%
As of Nov 2, 10:20 AM ET
559.49 Day range 568.67
409.47 52-week range 564.93
- YTD
- +24.51%
- 1 year
- +32.64%
- Open
- 559.93
- Prev close
- 558.88
- Mkt cap
- 142.80B
- Vol
- 510.74K
- Avg vol
- 1.20M
- EPS
- 17.17
- P/E
- 32.81
- Div yield
- 0.00%
More statistics
- Low
- 559.49
- High
- 568.67
- Forward P/E
- 27.40
- Beta
- 0.28
- Short ratio
- 3.66
- Inst. own
- 98.16%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 522.84
- 200-d avg
- 478.67
- 1y target
- 571.46
3M chart
Events in this range
- Aug 3, 2026Earnings: 4.73; estimate 4.74; surprise -0.21%
- Aug 4, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
- Aug 4, 2026Rating: TD Cowen · Buy → Buy
- Aug 5, 2026Rating: Barclays · Overweight → Overweight
- Aug 5, 2026Rating: Truist Securities · Buy → Buy
- Sep 28, 2026Rating: UBS · Buy → Buy
- Oct 8, 2026Rating: RBC Capital · Outperform → Outperform
Signals (16)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| SMA: Bearish | Oct 26, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Oct 1, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 4, 2026 | 1 month ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| RSI: Overbought | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
Financial health
Altman Z-Score
14.12 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
5 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
A-4 / 5 overall
- DCF 4
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 3
- P/E 2
- P/B 1
Valuation
P/E 29.3×
FY 2016 5y median 24.2× FY 2025
P/S 9.6×
FY 2016 5y median 9.4× FY 2025
P/B 6.2×
FY 2016 5y median 6.0× FY 2025
P/FCF 36.3×
FY 2016 5y median 23.5× FY 2025
EV/EBITDA 23.6×
FY 2016 5y median 20.7× FY 2025
EV/Sales 9.5×
FY 2016 5y median 9.2× FY 2025
FCF Yield 2.8%
FY 2016 5y median 3.1% FY 2025
Profitability
Gross Margin 85.0%
FY 2016 5y median 87.2% FY 2025
Operating Margin 39.4%
FY 2016 5y median 38.8% FY 2025
Net Margin 32.7%
FY 2016 5y median 32.7% FY 2025
ROE 21.2%
FY 2016 5y median 21.2% FY 2025
ROIC 18.1%
FY 2016 5y median 18.1% FY 2025
ROA 15.1%
FY 2016 5y median 15.9% FY 2025
Growth (YoY)
Revenue 9.6%
FY 2016 FY 2025
Operating Income 2144.1%
FY 2016 FY 2025
EPS (diluted) 836.5%
FY 2016 FY 2025
Free Cash Flow 504.1%
FY 2016 FY 2025
Financial Health
Current Ratio 2.9×
FY 2016 5y median 4.0× FY 2025
Quick Ratio 2.5×
FY 2016 5y median 3.8× FY 2025
Debt / Equity 0.2×
FY 2016 5y median 0.1× FY 2025
Net Debt / EBITDA -0.2×
FY 2016 5y median -2.1× FY 2025
Interest Coverage 358×
FY 2016 5y median 78.6× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31